Lv11
30 积分 2021-12-06 加入
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
25分钟前
待确认
Strategies for Structural Modification of Small Molecules to Improve Blood–Brain Barrier Penetration: A Recent Perspective
15天前
已完结
Can granulomatosis with polyangiitis be diagnosed earlier in primary care? A case–control study
25天前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
2个月前
已完结
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
2个月前
已完结
Combination locoregional and systemic therapies in hepatocellular carcinoma
2个月前
已完结
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
2个月前
已完结
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
2个月前
已完结
Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR
4个月前
已关闭
The Evolution of Treatment-Free Remission
4个月前
已完结
皖公网安备34019202002308
